|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The modification of natural products for medical use显示文摘Drug innovation is characterized by painstaking molecular-level syntheses and modifications as the basic components of research and development.Similarly,natural products are chemically tailored and modified based upon their structural and biological properties.To some extent,the modification of natural products is quite different from de novo structure-based drug discovery.This review describes the general strategies and principles for the modification of natural products to drugs,as illustrated by several successful medicines that originated from natural products. | Zongru Guo | 2017 | Acta Pharmaceutica Sinica B2017，7，2： | 14 |
| 2 | Artemisinin anti-malarial drugs in China显示文摘Discovered by Youyou Tu, one of the 2015 Nobel Prize winners in Physiology or Medicine,together with many other Chinese scientists, artemisinin, artemether and artesunate, as well as other artemisinins, have brought the global anti-malarial treatment to a new era, saving millions of lives all around the world for the past 40 years. The discoveries of artemisinins were carried out beginning from the 1970 s, a special period in China, by hundreds of scientists all together under the 'whole nation'system. This article focusing on medicinal chemistry research, briefly introduced the discovery and invention course of the scientists according to the published papers, and highlighted their academic contribution and achievements. | Zongru Guo | 2016 | Acta Pharmaceutica Sinica B2016，6，2： | 11 |
| 3 | Expression levels of induced sputum IL?8 and IL?10 and drug interventioneffects in patients with acute exacerbated COPD complicated with chronic cor pulmonaleat high altitude显示文摘 | Enzhi Feng Ronghua Wan Shengyue Yang Ziqiang Yan Shaolin Wang Wei He Ying Zhang He Yin Zongru Chen Ruinian Liu | 2013 | Experimental and Therapeutic Medicine2013，，3： | 1 |
| 4 | Expression levels of induced sputum IL?8 and IL?10 and drug interventioneffects in patients with acute exacerbated COPD complicated with chronic cor pulmonaleat high altitude显示文摘 | Enzhi Feng Ronghua Wan Shengyue Yang Ziqiang Yan Shaolin Wang Wei He Ying Zhang He Yin Zongru Chen Ruinian Liu | 2013 | Experimental and Therapeutic Medicine2013，，3： | 1 |
| 5 | Medicinal chemistry strategies in follow-on drug discovery 显示文摘 | Hongyu Zhao Zongru Guo | 2009 | Drug Discovery Today2009，14，910： | 1 |
| 6 | The role of microRNA in the delayed negative feedback regulationof gene expression 显示文摘 | Xie Zongru Yang HsihTe Liu Weichung | 2007 | Biochem Biophys Res Commun2007，358，3： | 1 |
| 7 | Medicinal chemistry strategies in follow-on drug discovery 显示文摘 | Zhao Hongru R Guo Zongru | 2009 | Drug Dis- covery Today2009，14，910： | 1 |
| 8 | Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies显示文摘Enhancer of zeste homolog 2(EZH2),an enzymatic subunit of PRC2 complex,plays an important role in tumor development and progression through its catalytic and noncatalytic activities.Overexpression or gain-of-function mutations of EZH2 have been significantly associated with tumor cell proliferation of triple-negative breast cancer(TNBC)and diffuse large B-cell lymphoma(DLBCL).As a result,it has gained interest as a potential therapeutic target.The currently available EZH2 inhibitors,such as EPZ6438 and GSK126,are of benefit for clinical using or reached clinical trials.However,certain cancers are resistant to these enzymatic inhibitors due to its noncatalytic or transcriptional activity through modulating nonhistone proteins.Thus,it may be more effective to synergistically degrade EZH2 in addition to enzymatic inhibition.Here,through a rational design and chemical screening,we discovered a new irreversible EZH2 inhibitor,IHMT-337,which covalently bounds to and degrades EZH2 via the E3 ligase CHIP-mediated ubiquitination pathway.Moreover,we revealed that IHMT-337 affects cell cycle progression in TNBC cells through targeting transcriptional regulating of CDK4,a novel PRC2 complex-and enzymatic activity-independent function of EZH2.More significantly,our compound inhibits both DLBCL and TNBC cell proliferation in different preclinical models in vitro and in vivo.Taken together,our findings demonstrate that in addition to enzymatic inhibition,destroying of EZH2 by IHMT-337 could be a promising therapeutic strategy for TNBC and other malignancies that are independent of EZH2 enzymatic activity. | Husheng Mei Hong Wu Jing Yang Bin Zhou Aoli Wang Chen Hu Shuang Qi Zongru Jiang Fengming Zou Beilei Wang Feiyang Liu Yongfei Chen Wenchao Wang Jing Liu Qingsong Liu | 2023 | Signal Transduction and Targeted Therapy2023，8，2： | 0 |
| 9 | Observation on Efficacy of Kurarinone Treating Chronic Hepatitis B显示文摘 | HAN Zongru | 2005 | 美国中华健康卫生杂志2005，8，4： | 0 |
| 10 | Integrated genomic analyses identify high-risk factors and actionable targets in T-cell acute lymphoblastic leukemia显示文摘T cell acute lymphoblastic leukemia(T-ALL)is an aggressive hematologic malignancy often associated with poor outcomes.To identify high-risk factors and potential actionable targets for T-ALL,we perform integrated genomic and transcriptomic analyses on samples from 165 Chinese pediatric and adult T-ALL patients,of whom 85%have outcome information.The genomic mutation landscape of this Chinese cohort is very similar to the Western cohort published previously,except that the rate of NOTCH1 mutations is significant lower in the Chinese T-ALL patients.Among 47 recurrently mutated genes in 7 functional categories,we identify RAS pathway and PTEN mutations as poor survival factors for non-TAL and TAL subtypes,respectively.Mutations in the PI3K pathway are mutually exclusive with mutations in the RAS and NOTCH1 pathways as well as transcription factors.Further analysis demonstrates that approximately 43%of the high-risk patients harbor at least one potential actionable alteration identified in this study,and T-ALLs with RAS pathway mutations are hypersensitive to MEKi in vitro and in vivo.Thus,our integrated genomic analyses not only systematically identify high-risk factors but suggest that these high-risk factors are promising targets for T-ALL therapies. | Haichuan Zhu Bingjie Dong Yingchi Zhang Mei Wang Jianan Rao Bowen Cui Yu Liu Qian Jiang Weitao Wang Lu Yang Anqi Yu Zongru Li Chao Liu Leping Zhang Xiaojun Huang Xiaofan Zhu Hong Wu | 2022 | Blood Science2022，4，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员